Companies To Watch: KaliVir Immunotherapeutics
By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein
Engineering oncolytic viruses with novel transgenes, and joining them to other immunotherapies, to defeat cancer and cancer relapse
SNAPSHOT
KaliVir Immunotherapeutics is developing oncolytic viruses, based on its VET (vaccinia enhanced template) platform, to fight solid- tumor cancers intravenously. The platform employs modified viruses and transgenes to trigger several modes of action against tumors by various factors expressed in the engineered viruses. The company now has four products in preclinical development: VET3- TGI (ASP1012, licensed to Astellas) expressing IL-12 and a TFG-ß inhibitor, VET2-L2, which effects T-cell reprogramming to enhance tumor killing, and earlier-stage candidates, VET-AST2 and VET-ROG, in discovery with Astellas and Roche, respectively, with undisclosed modes of action.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.